



Vicore Pharmas acquisition of INIM Pharma completed

The Board in Vicore Pharma Holding AB (publ) (ticker: VICO) can today announce that the acquisition of INIM Pharma AB, which is implemented through an issue in kind and decided by the Extraordinary General Meeting on August 13, 2018, was finalized. Vicore Pharma Holding AB has thus acquired the shares in INIM Pharma AB. HealthCap will be the largest shareholder in Vicore Pharma Holding with 30.4% ownership after the issue in kind is registered.

For more information, please contact;

Per Jansson, CEO +46 70 917 47 46, per.jansson@vicorepharma.com

About Vicore Pharma Holding

Vicore Pharma AB develops drugs that act through the AT2 receptor. The company's drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com.